1985sek
5,9 %
Date:2025-07-16Time:18:00:00Latest report:Q1-2025List:First NorthTicker:GUARD
Market Cap:400 msekEnterprise Value:384 msekNet Sales:- msekEarnings:-115,8 msekEmployees:0ISIN:SE0021181559

Ratios

10-year key figure history for Guard Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Guard Therapeutics with index and moving average MA50 and MA200.

Stockprice:19,85
MA50:16,86
MA200:19,77
Price/MA200:0,4 %
RSI (14):68,1
Price/MA50:17,7 %

Description

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Biotechnology